Premium
the role of autologous tumor cells in preventing lymphokine‐activated killer cell induction in vitro
Author(s) -
Slovin Susan F.,
Maguire Henry C.,
Mastrangelo Michael J.
Publication year - 1990
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19901215)66:12<2541::aid-cncr2820661216>3.0.co;2-r
Subject(s) - lymphokine activated killer cell , lymphokine , cytotoxicity , immunology , interleukin 2 , k562 cells , in vitro , cancer research , natural killer cell , natural killer t cell , major histocompatibility complex , medicine , biology , immune system , interleukin 21 , t cell , leukemia , biochemistry
Peripheral blood lymphocytes (PBL), when cultured in vitro in the presence of autologous irradiated tumor and interleukin‐2 (IL‐2), become more restricted in the spectrum of their cytotoxicity. the cells continue to exhibit cytotoxicity for autologous tumor cells and major histocompatibility complex (MHC)‐concordant allogeneic tumor cells of similar histologic type but not for the natural killer target cell line, K562. Furthermore, the addition of autologous tumor at different time points after the initiation with IL‐2 alone of conventional lymphokine‐activated killer cell cultures modifies both the specificity and the degree of cytotoxicity of these lymphocytes for tumor targets. By varying the culture conditions it may be possible to generate killer cells that will exhibit similarly enhanced and more restricted antitumor effects in vivo .